Filtered By:
Source: Heart Rhythm
Condition: Atrial Fibrillation

This page shows you your search results in order of relevance. This is page number 20.

Order by Relevance | Date

Total 356 results found since Jan 2013.

EP News Clinical February 2022
Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke
Source: Heart Rhythm - February 2, 2022 Category: Cardiology Authors: N. A. Mark Estes Source Type: research

Procedural and Short-Term Follow-Up Outcomes of Amplatzer Amulet Occluder versus Watchman FLX Device: A Meta-Analysis
Left atrial appendage (LAA) occlusion provides effective protection against thromboembolic (TE) events in high-risk atrial fibrillation patients. Two percutaneous devices are currently available in the United States for stroke prophylaxis: the WatchmanTM device (Boston Scientific, USA) and the AmplatzerTM AmuletTM Left Atrial Appendage Occluder (Abbott, USA). The latter has recently received Food and Drug Administration approval as a result of the findings of the Amulet IDE randomized trial (1), which showed superiority for LAA occlusion (lower rates of leaks>5mm) based on a comparison between the second generation Amplatz...
Source: Heart Rhythm - February 11, 2022 Category: Cardiology Authors: Domenico G. Della Rocca, Michele Magnocavallo, Carola Gianni, Sanghamitra Mohanty, Veronica N. Natale, Amin Al-Ahmad, Carlo Lavalle, Rodney P. Horton, Luigi Di Biase, Andrea Natale Source Type: research

EP News: Allied Professionals
In this non-prespecified, post hoc analysis of the AUGUSTUS (The Open-Label, 2 x 2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention) trial (Harskamp et al. J Am Coll Cardiol. 2022;79:417-27. PMID-35115097), the authors sought to evaluate whether the risk of bleeding or stroke as assessed by baseline HAS-BLED and CHA2DS2-VASc scores affected the results of the trial.
Source: Heart Rhythm - March 9, 2022 Category: Cardiology Authors: Erica S. Zado Source Type: research

Incidence of new onset atrial fibrillation after transcatheter pfo closure using 15 years of ontario administrative health data
Individuals with patent foramen ovale (PFO) routinely undergo transcatheter closure (TC) for secondary prevention of recurrent stroke. However, there has been some evidence suggesting that TC may increase the risk of new-onset atrial fibrillation (AF).
Source: Heart Rhythm - April 13, 2022 Category: Cardiology Authors: Laura Oliva, Ella Huszti, Ruth Hall, Lusine Abrahamyan, Eric Horlick Source Type: research

Liver cirrhosis is independently associated with increased in-hospital mortality in patients undergoing left atrial appendage occlusion device implantation
This study aimed to assess procedural outcomes in patients with cirrhosis who underwent LAAO with a Watchman device by using a contemporary administrative claims database.
Source: Heart Rhythm - April 28, 2022 Category: Cardiology Authors: Sahith Reddy Thotamgari, Aakash R. Sheth, Harsh P. Patel, John Bretzman, Robert C. Ward, Samarthkumar Thakkar, Jaimin T. Patel, Samuel J. Asirvatham, David R. Holmes, Alexander Egbe, Abhishek Deshmukh, Christopher V. DeSimone Tags: Research Letter Source Type: research

Adverse events associated with the AtriClip device for left atrial appendage occlusion: A Food and Drug Administration MAUDE database study
Based on autopsy studies, the left atrial appendage has been implicated as the cause of stroke in>90% of cases with nonvalvular atrial fibrillation. The AtriClip device (Atricure, West Chester, OH) is used for left atrial appendage exclusion at the time of median sternotomy or thoracoscopically (as a  stand-alone procedure or at the time of hybrid epicardial-endocardial ablation for atrial fibrillation).1–3 The real-world safety profile of AtriClip has not been evaluated, and we analyzed adverse events related to its use reported to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.
Source: Heart Rhythm - April 28, 2022 Category: Cardiology Authors: Tahmeed Contractor, Rahul Bhardwaj, Ravi Mandapati, Kamal Kotak, Jalaj Garg Tags: Research Letter Source Type: research

Po-718-05 prescribing patterns of direct anticoagulants versus vitamin k antagonists in patients with non-valvular atrial fibrillation and extreme obesity
Anticoagulation is an effective treatment in prevention of stroke in patients with atrial fibrillation (AF). Direct anticoagulants (DOACs) have been favored over vitamin K dependent antagonists (VKAs) given their safety and efficacy. However, there is limited real-world data on DOAC use among patients with extreme obesity.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Sherry J. Saxonhouse, Kamala SWAYAMPAKALA, Stephen Perle, Sophia E. Saxonhouse Source Type: research

Po-718-03 identifying and characterizing patients with atrial fibrillation and elevated thromboembolic risk who are not appropriately anticoagulated
Atrial fibrillation (AF) is the leading cause of stroke, which can be reduced by 70% with appropriate use of anticoagulation therapy. Nationally, appropriate anticoagulation rates for patients with AF with elevated thromboembolic risk are as low as 50% even across the highest CHADS2VASC score cohorts. Understanding anticoagulation fallout rates among gender, ethnicity, and socioeconomic status is an important first step towards decreasing the risk of thromboembolic events.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Sushmita Malik, Rachel Huai-En Chang, Shanshan Gustafson, Yonas Tamrat, Natalia Berry Source Type: research

Po-716-08 real world clinical outcomes of left atrial appendage occlusion device in the octogenarian and nonagenarian patients
Few trials evaluated real world clinical outcomes in patients with atrial fibrillation receiving the Watchman device for left atrial appendage closure. In the recent Ewolution trial, mean age of patients was 73.4 + 8 years. Although few patients> 80 years were included, the safety and efficacy in terms of clinical outcomes of stroke, bleeding and mortality in the octogenarian and nonagenarian population specifically has not been reported in real world setting.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Javier Amione Guerra, Justin Haloot, Ahmed Almomani, David N. Pederson, Jayasree Pillarisetti Source Type: research

Po-716-02 short term readmission rates and clinical outcomes of anticoagulation versus watchman device in octogenarians
Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia with prevalence increasing with age. Left atrial appendage occlusion (LAAO) with watchman device has been found to be noninferior to oral anticoagulation for long-term stroke risk reduction in patients with AF. Patients greater than 80 years of age have been underrepresented in most of these trials making application of findings challenging in this subset of patients.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Varun Victor, Mahmoud Khalil, Ahmed Mohamed, Kirolos Barssoum Source Type: research

Po-639-03 3d mapping facilitated, intra-cardiac echocardiography (ice) guided left atrial appendage occlusion (laao) is feasible and safe, providing similar efficacy with less personnel than transesophageal echocardiography (tee) guided procedures
Left atrial appendage occlusion (LAAO) provides an alternative for stroke prevention in patients with atrial fibrillation who cannot be safely anticoagulated long-term. WATCHMAN FLX placement was described, and is traditionally performed, with transesophageal echocardiography (TEE) guidance under general anesthesia (GA). The implanting physician, echocardiography team, and anesthesia team must all be present, complicating coordination and scheduling. The use of intracardiac echocardiography (ICE) with 3D mapping guidance in place of TEE for LAAO procedures can eliminate the need for additional personnel.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Iva Minga, Mark D. Metzl, Jonathan Rosenberg, Jose Nazari Source Type: research

Po-626-03 preclinical safety of adkcnh2-g628s for post-op af
Post-operative atrial fibrillation (POAF) occurs in 30% of cardiac surgeries, increasing risk of stroke, MI, and death. We propose gene therapy with an adenovirus encoding the G628S mutation of KCNH2 (AdKCNH2-G628S) to prevent POAF. We have reported preclinical efficacy in pigs.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: J. Kevin Donahue, David D. McManus Source Type: research

Po-620-04 intra-operative findings with massive device-related thrombus after percutaneous left atrial appendage closure: mechanistic insights
Left atrial appendage closure (LAAC) devices are an alternative to antithrombotic therapy for stroke prevention in high-risk patients with atrial fibrillation who are not candidates for systemic anticoagulation. However, device related thrombus (DRT) has an observed incidence of ∼4% after LAAC. The mechanism of massive thrombus formation remains incompletely understood.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Kashif Malik, Rong Bai, Damir Vukomanovic, Alicia Taase, Eleanor Kitchell, Rinku Skaria, Roderick Tung, Kenith Fang, Michael S. Zawaneh Source Type: research

Po-614-05 a community hospital review of watchman outcomes to determine safe discharge protocols
Left atrial appendage occlusion (LAAO) devices are increasingly used to decrease the risk of stroke in atrial fibrillation patients with contraindication to oral anticoagulation. Discharge protocols after this procedure are variable, and same day discharge (SDD) may improve inpatient bed utilization.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Jill Boone Schaeffer, Diane N. Bollinger Source Type: research

En-571-02 screening for putative pathogenic variants in dilated cardiomyopathy genes identifies early disease and predicts mortality
Dilated cardiomyopathy (DCM) can present with the sentinel event of sudden cardiac death, as well as heart failure, ECG abnormalities, atrial fibrillation or stroke. Data are limited regarding genetic screening and the mortality associated with DCM in a general population.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Ravi Shah, Babken Asatryan, Ghaith Sharaf Dabbagh, Mohammed Khanji, Stefan van Duijvenboden, Daniele Muser, Andrew Paul Landstrom, Christopher Semsarian, Virend Somers, Patricia B. Munroe, Anwar A. Chahal Source Type: research